Latest Commercialization News

Metal Powder Works reported a stellar December quarter with a threefold increase in CP-Ti orders, expansion into precious metals, and strategic contracts that position it strongly in defence and advanced manufacturing markets.

Imricor Medical Systems has secured Virginia Commonwealth University Health as the third US site for its VISABL-AFL clinical trial, advancing its FDA approval pathway for MRI-guided cardiac ablation technology.

Algorae Pharmaceuticals has locked in a $3 million revolving debt facility with ScotPac, providing flexible, non-dilutive funding to accelerate its commercial operations across Australia and New Zealand.

Noxopharm has successfully completed the final multiple-dose cohort of its HERACLES trial for SOF-SKN™, reporting no significant safety concerns and paving the way for Phase II-enabling studies.

St George Mining has extended its strategic alliance with US rare earths processor REalloys to finalise potential offtake agreements for high-grade rare earths from the Araxá Project in Brazil. This move aligns with US efforts to build independent rare earth supply chains critical for defence and green technologies.

BCAL Diagnostics has launched its Avantect pancreatic and ovarian cancer tests in Australia, alongside expanding clinical data and establishing a national registry for its BREASTESTplus breast cancer test.

AdAlta Limited has aligned its AdCella manufacturing strategy with new US FDA guidelines, made a significant milestone payment to Shanghai Cell Therapy Group, and secured an additional R&D tax rebate, marking key progress in its cellular immunotherapy pipeline.

Vulcan Energy has reported strong production test results from its LSC-1b sidetrack well, reinforcing the viability of its Phase One Lionheart lithium project in Germany. The well’s performance supports the project’s ambitious lithium and renewable energy production targets.

Anteris Technologies has launched a $200 million public offering alongside a $90 million strategic investment from Medtronic, aiming to accelerate its DurAVR heart valve clinical trials and manufacturing expansion.

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

VHM Limited has made significant strides in developing its Goschen Rare Earths and Mineral Sands Project, securing substantial funding and critical regulatory approvals while expanding its resource base.

Firebrick Pharma has introduced its Nasodine Throat Spray in Singapore, marking its first international product launch and setting the stage for further global rollouts in 2026.